A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19) Clinical Trial

Official title:

A Phase 3, Single Arm, Open-Label Trial to Evaluate the Immunogenicity and Safety of a Single Heterologous Booster Vaccination of TAK-019 in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05299359
• Other study ID #: TAK-019-3001
• Secondary ID: jRCT2071210141U1
• Status: Completed
• Phase: Phase 3
• Start date: April 15, 2022
• Est. completion date: October 18, 2023

Study information

• Verified date: November 2023
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019 for participants who will receive TAK-019 as heterologous booster vaccination.

This study consists of two parts, main part and extension part. Firstly, participants who completed 2 doses primary vaccinations 6 to 12 months prior to the trial vaccination can take part in main study. At the first visit of main part of this study, the study doctor will check if each person can take part. Participants who can take part will receive an injection of TAK-019 as booster vaccination.

Participants will be asked to record their temperature and any medical problems in an electronic diary for up to 7 days after the injection. During the main part, participants will visit the clinic for regular check-ups, blood tests, and sometimes for nose swab samples. When all participants have attended a clinic visit 28 days after the injection, the study sponsor (Takeda) will check how many participants have made enough antibodies to protect them against Covid-19.

Participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will be able to decide to take part in the extension part of this study. At the first visit of extension part of this study, the study doctor will check if each person can take part. Participants who can take part will receive an injection of TAK-019 as a second booster vaccination at the first visit of extension part.

The participants will stay in the main part of this study for up to 12 months after they have had their injection or up to the start of extension part. For participants who will take part in the extension part, they will stay in the extension part for up to 12 months from the start of extension part. During this time, the doctors will continue to collect blood samples to check immune response. Also, they will check if participants have any more side effects from TAK-019.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: October 18, 2023
• Est. primary completion date: June 11, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

MAIN PART:

1. Healthy Japanese male and female adult participants aged >= 20 years of age at the time of signing of informed consent.

2. Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine which is available in Japan 6 to 12 months prior to the trial vaccination.

EXTENSION PART:

3. Participants who received the first trial vaccination at least 5 months earlier and are currently enrolled in the Main Part (ie, not have withdrawn or discontinued early).

Exclusion Criteria:

MAIN PART:

1. Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.

2. Participant who received a booster vaccination (i.e. 3rd dose)

3. Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.

4. Participants who were tested positive for SARS-CoV-2 prior to the trial.

5. Participants who have traveled outside of Japan in the 30 days prior to the trial participation.

6. Participants with a clinically significant active infection or oral temperature >= 38 degree Celsius within 3 days of the intended date of the first single booster vaccination.

7. Participants with body mass index (BMI) greater than or equal to 30 kg/m^2 (BMI= weight in kg/ height in meters^2)

EXTENSION PART:

8. Participants with a clinically significant active infection or oral temperature >=38 degree Celsius within 3 days of the intended date of the second single booster vaccination.

Related Conditions & MeSH terms

• Coronavirus Disease (COVID-19)
• COVID-19

Intervention

Biological:
• TAK-019
TAK-019 intramuscular injection

Locations

Country	Name	City	State
Japan	PS Clinic	Fukuoka
Japan	Sumida Hospital	Sumida-ku	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study	GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 20. GMT for each group and GMT ratio of neutralizing antibody titers to the ancestral strain (wild-type virus) on Day15 after a single booster vaccination (14 days after the booster vaccination) compared with that observed on Day 36 (14 days after the second vaccination) in participants from the TAK-019-1501 study (NCT04712110) were reported. GMT ratio was calculated with GMT of TAK-019-3001 on Day 15 divided by GMT of TAK-019-1501 study on Day 36. Here, ELISA is Enzyme-linked immunosorbent assay.	Day 15 for this study (14 days after the vaccination); Day 36 for TAK-019-1501 study (14 days after the second vaccination)
Primary	Main Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination	AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.	7 days after the first single booster vaccination
Primary	Main Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination	Solicited systemic AEs were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting, and headache.	7 days after the first single booster vaccination
Primary	Main Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination	Unsolicited AEs defines as other AEs than solicited local AEs and solicited systemic AEs.	28 days after the first single booster vaccination
Primary	Main Part: Percentage of Participants With Serious Adverse Events (SAE) Until Day 29	An SAE was defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event. Solicited SAEs and Unsolicited SAEs were reported,	Up to Day 29
Primary	Main Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 29	An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the Potential Immune Mediated Medical Conditions (PIMMC) and AEs specific to COVID-19. PIMMC is categorized as following; Neuroinflammatory Disorders, Musculoskeletal and Connective Tissue Disorders, Vasculitides, Gastrointestinal Disorders, Hepatic Disorders, Renal Disorders, Cardiac Disorders, Skin Disorder, Hematologic Disorders, Metabolic Disorders, and Other Disorders.	Up to Day 29
Primary	Main Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 29		Up to Day 29
Primary	Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 29		Up to Day 29
Primary	Main Part: Percentage of Participants With SARS-CoV-2 Infection Until Day 29		Up to Day 29
Secondary	Main Part: GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366		Day 8, 15, 29, 91, 181, and 366
Secondary	Main Part: Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366		Day 8, 15, 29, 91, 181, and 366
Secondary	Main Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366	SCR is defined at percentage of participants with >= 4-fold rises from baseline (Day 1).	Day 8, 15, 29, 91, 181, and 366
Secondary	Main Part: GMT of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366		Day 8, 15, 29, 91, 181, and 366
Secondary	Main Part: GMFR of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366		Day 8, 15, 29, 91, 181, and 366
Secondary	Main Part: SCR of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366	SCR is defined at percentage of participants with >= 4-fold rises from baseline (Day 1).	Day 8, 15, 29, 91, 181, and 366
Secondary	Main Part: Percentage of Participants With SAE Throughout the Trial		Up to Day 366
Secondary	Main Part: Percentage of Participants With AESI Throughout the Trial		Up to Day 366
Secondary	Main Part: Percentage of Participants With MAAEs Throughout the Trial		Up to Day 366
Secondary	Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Trial		Up to Day 366
Secondary	Main Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial		Up to Day 366
Secondary	Extension Part: GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, Day 29, Day 91, Day 181, and Day 366		Day 15, 29, 91, 181, and 366
Secondary	Extension Part: GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, Day 29, Day 91, Day 181, and Day 366		Day 15, 29, 91, 181, and 366
Secondary	Extension Part: SCR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, Day 29, Day 91, Day 181, and Day 366	SCR is defined at percentage of participants with >= 4-fold rises from baseline (Extension Part Day 1).	Day 15, 29, 91, 181, and 366
Secondary	Extension Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, Day 29, Day 91, Day 181, and Day 366		Day 15, 29, 91, 181, and 366
Secondary	Extension Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, Day 29, Day 91, Day 181, and Day 366		Day 15, 29, 91, 181, and 366
Secondary	Extension Part: SCR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, Day 29, Day 91, Day 181, and Day 366	SCR is defined at percentage of participants with >= 4-fold rises from baseline (Extension Part Day 1).	Day 15, 29, 91, 181, and 366
Secondary	Extension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination		7 days
Secondary	Extension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination		7 days
Secondary	Extension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination		28 days
Secondary	Extension Part: Percentage of Participants With SAEs Until Extension Part Day 29		From Day 1 to Day 29
Secondary	Extension Part: Percentage of Participants With AESIs Until Extension Part Day 29		From Day 1 to Day 29
Secondary	Extension Part: Percentage of Participants With MAAEs Until Extension Part Day 29		From Day 1 to Day 29
Secondary	Extension Part: Percentage of Participants With Any AEs Leading to Participant's Withdrawal From the Trial Until Extension Part Day 29		From Day 1 to Day 29
Secondary	Extension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 29		From Day 1 to Day 29
Secondary	Extension Part: Percentage of Participants With SAEs Throughout the Extension Part		From Day 1 to Day 366
Secondary	Extension Part: Percentage of Participants With AESIs Throughout the Extension Part		From Day 1 to Day 366
Secondary	Extension Part: Percentage of Participants With MAAEs Throughout the Extension Part		From Day 1 to Day 366
Secondary	Extension Part: Percentage of Participants With Any AEs Leading to Participant's Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part		From Day 1 to Day 366
Secondary	Extension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part		From Day 1 to Day 366

External Links

•   To obtain more information on the study, click here/on this link